Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial

Abstract

Background The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbiological efficacy of antibiotics on day 20 of treatment, we conducted an open-label randomized trial based on clinical outcomes, microbiological clearance, spirometry tests, and signs of systemic inflammation in patients hospitalized with acute exacerbations of COPD. Methods We enrolled 139 subjects with COPD exacerbations, defined as acute worsening of respiratory symptoms leading to additional treatment. Patients were divided randomly into two groups: 79 patients using beta-lactam antibiotics alone and 60 using beta-lactam antibiotics plus fluoroquinolones. Clinical and microbiological responses, spirometry tests, symptom scores, and serum C-reactive protein (CRP) levels were evaluated. Results Clinical success, lung function, and symptoms were similar in patients with or without fluoroquinolone administration on days 10 and 20. Combination therapy was superior in terms of microbiological outcomes and reduction in serum CRP value. Although equivalent to monotherapy in terms of clinical success, the combination showed superiority in terms of microbiological success and a decrease in CRP. The combination therapy group had a higher microbiological success rate with gram-negative bacteria than the monotherapy group with Pseudomonas aeruginosa (100% vs. 33.3%, respectively) and Acinetobacter baumanii (100% vs. 20%, respectively) (P < 0.05). Conclusions Concomitant use of fluoroquinolone and beta-lactam antibiotics for bacterial infections during COPD exacerbations caused by gram-negative bacteria appear to be effective and should be applied in clinical practice.

Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions

“…In the current landscape marked by an escalation of antibiotic-resistant infections, the strategic application of empiric antimicrobial therapy, employing multiple agents, is increasingly recognized as a means to enhance coverage against suspected pathogens [ 69 , 76 , 77 ]. The timely initiation of an effective antimicrobial regimen is essential for the management of seriously ill patients where bacterial infections are implicated [ 69 ].…”

Combating Antimicrobial Resistance: A paradigm shift from general to precision medicine

“…Combination antibiotic therapy increases the antibacterial spectrum and can target a wide range of bacteria, especially when infection is caused by multiple or unknown pathogens. 62,63 It can prevent or delay the development of resistance. This can preserve the efficacy of existing antibiotics and extend their clinical usefulness.…”

Nanoparticles Based Combined Antimicrobial Drug Delivery System as a Solution for Bacterial Resistance

“…Antibiotic combinations are the final choice when multiple antibiotic resistances are encountered, and they are the standard of care for critically ill patients 8 . Antibiotic combinations are assumed to be the most effective way to combat multiple resistance caused by antimicrobial monotherapy 9 . Furthermore, antibiotic combinations increase the spectrum coverage supplied by two antimicrobial drugs with different spectra of activity and lowering resistance emergence 8 .…”